Inventiva S.A.
http://www.inventivapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inventiva S.A.
Bangers In MASH: How Rezdiffra's Rivals Stack Up
A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.
Ionis Could Be A Factor In MASH With Positive Phase II Data
Ionis’s DGAT2 inhibitor showed potential to improve disease activity score and resolve metabolic-associated steatohepatitis in a Phase II study, but analysts point to fibrosis-reduction data as competitively intriguing.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Inventiva Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice